Premium
Nalbuphine for obstetric analgesia
Author(s) -
FRANK M.,
McATEER E. J.,
CATTERMOLE R.,
LOUGHNAN B.,
STAFFORD L. B.,
HITCHCOCK A. M.
Publication year - 1987
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.1987.tb05313.x
Subject(s) - nalbuphine , medicine , pethidine , anesthesia , sedation , apgar score , statistical significance , pregnancy , obstetrics , opioid , analgesic , fetus , receptor , biology , genetics
Summary A double‐blind, randomised study of 60 patients who received intravenous increments of nalbuphine 3 mg or pethidine 15 mg by patient‐controlled analgesia during the first stage of labour, was carried out. Pain intensity, sedation, uterine contractions, maternal cardioventilatory variables and fetal heart rate were recorded as well as any side effects. Apgar scores, time to sustained respiration and resuscitative measures required for the neonate were noted at delivery. Modified neonatal neurobehavioural studies and a retrospective assessment of maternal analgesia, satisfaction and tolerance were also carried out. Group mean values of pain scores of nalbuphine‐medicated primiparous women were statistically significantly lower than those of pethidine‐medicated patients (p < 0.01). Other assessments did not demonstrate a statistical significance between the two groups.